| Literature DB >> 35282588 |
Vanessa Abreu Sanches Marques Costa1,2, Carlos Roberto Emerenciano Bueno1,2, Diego Valentim1, Francine Benetti1,3, Marina Tolomei Sandoval Cury1, Ana Maria Veiga Vasques1, Edilson Ervolino4, Eloi Dezan-Junior1.
Abstract
Aims: The aim of this study was to evaluate the biocompatibility of resinous root canal sealers: Sealer 26, AH plus, and SK Seal Root Canal Sealer in the subcutaneous tissue of rats. Subjects andEntities:
Keywords: Biocompatibility; materials testing; tenascin
Year: 2022 PMID: 35282588 PMCID: PMC8896128 DOI: 10.4103/jcd.jcd_628_20
Source DB: PubMed Journal: J Conserv Dent ISSN: 0972-0707
Figure 1Representative images of tissue reaction of groups. Control Group: (A-D) (days 7, 15, 30 and 60, H and E, ×100); AH Plus: (E-H) (days 7, 15, 30 and 60, H and E, ×100); Sealer 26: I-L (days 7, 15, 30 and 60, H and E, ×100) and SK Seal Root Canal Sealer: M-P (days 7, 15, 30 and 60, H and E, ×100)
Figure 2Representative images of immunolabeling for fibronectin (A-P) and tenascin (a-p). Control Group: A-D; a-d (days 7, 15, 30 and 60); AH Plus: E-H; e-h (days 7, 15, 30 and 60); Sealer 26: I-L; i-l (days 7, 15, 30 and 60); SK Seal Root Canal Sealer: M-P; m-p (days 7, 15, 30 and 60, ×1000)
Percentage of samples in each group according to the inflammation score and fibrous capsule thickness
| Groups | Scores |
| Capsule | ||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | Med | |||
| 7 days | |||||||
| Control | 0 | 0 | 6 | 0 | 2a | 0.601 | Thick |
| AH plus | 0 | 0 | 6 | 0 | 2a | Thick | |
| Sealer 26 | 0 | 2 | 4 | 0 | 2a | Thick | |
| Sk Seal | 0 | 3 | 1 | 2 | 1a | Thin | |
| 15 days | |||||||
| Control | 0 | 1 | 5 | 0 | 2a | 0.235 | Thick |
| AH Plus | 0 | 2 | 4 | 0 | 2a | Thin | |
| Sealer 26 | 0 | 0 | 6 | 0 | 2a | Thick | |
| Sk Seal | 0 | 3 | 3 | 0 | 1/2a | Thin | |
| 30 days | |||||||
| Control | 0 | 6 | 0 | 0 | 1a | 0.074 | Thin |
| AH Plus | 0 | 2 | 4 | 0 | 2a | Thin | |
| Sealer 26 | 0 | 2 | 3 | 1 | 2a | Thin | |
| Sk Seal | 0 | 3 | 3 | 0 | 1/2a | Thin | |
| 60 days | |||||||
| Control | 2 | 4 | 0 | 0 | 1a | 0.901 | Thin |
| AH Plus | 2 | 4 | 0 | 0 | 1a | Thin | |
| Sealer 26 | 2 | 4 | 0 | 0 | 1a | Thin | |
| Sk Seal | 1 | 5 | 0 | 0 | 1a | Thin | |
*Different letters in the same column indicate that there is statistical difference between the groups in each analysis period (P<0.05)
Percentage of scores attributed to fibronectin and tenascin immunolabeling in each group
| Groups | Score fibronectin |
| Score tenascin |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | Med | 0 | 1 | 2 | 3 | Med | |||
| 7 days | ||||||||||||
| Control | 0 | 5 | 1 | 0 | 1a | 0.001 | 0 | 4 | 2 | 0 | 1a | 0.006 |
| AH Plus | 0 | 0 | 5 | 1 | 2b | 0 | 0 | 5 | 1 | 2ab | ||
| Sealer 26 | 0 | 0 | 6 | 0 | 2ab | 0 | 0 | 6 | 0 | 2ab | ||
| Sk Seal | 0 | 0 | 2 | 0 | 2ab | 0 | 0 | 3 | 3 | 2/3b | ||
| 15 days | ||||||||||||
| Control | 0 | 5 | 1 | 0 | 1a | 0.005 | 0 | 5 | 1 | 0 | 1a | 0.005 |
| AH Plus | 0 | 0 | 4 | 2 | 2ab | 0 | 0 | 4 | 2 | 2b | ||
| Sealer 26 | 0 | 0 | 3 | 3 | 2/3b | 0 | 2 | 4 | 0 | 2ab | ||
| Sk Seal | 0 | 0 | 3 | 3 | 2/3b | 0 | 0 | 4 | 2 | 2b | ||
| 30 days | ||||||||||||
| Control | 0 | 5 | 1 | 0 | 1a | 0.002 | 0 | 6 | 0 | 0 | 1a | 0.002 |
| AH Plus | 0 | 0 | 6 | 0 | 2ab | 0 | 0 | 4 | 2 | 2b | ||
| Sealer 26 | 0 | 0 | 5 | 1 | 2ab | 0 | 1 | 5 | 0 | 2ab | ||
| Sk Seal | 0 | 0 | 4 | 2 | 2b | 0 | 4 | 2 | 0 | 1ab | ||
| 60 days | ||||||||||||
| Control | 0 | 6 | 0 | 0 | 1a | <0.001 | 0 | 5 | 1 | 0 | 1a | 0.006 |
| AH Plus | 0 | 0 | 4 | 2 | 2b | 0 | 0 | 4 | 2 | 2b | ||
| Sealer 26 | 0 | 0 | 5 | 1 | 2b | 0 | 1 | 5 | 0 | 2ab | ||
| Sk Seal | 0 | 0 | 2 | 0 | 2ab | 0 | 4 | 2 | 0 | 1ab | ||
*Different letters in the same column indicate that there is statistical difference between the groups in each analysis period (P<0.05)